CTX — Crescita Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$14.71m
- CA$8.50m
- CA$21.12m
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium
Canadian dermatology company Crescita Q3 revenue up 50% on manufacturing growth
Crescita Therapeutics swings to Q2 profit as revenue rises over 50%
Brief: Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis
Brief: Crescita Therapeutics Announces Approval Of Normal Course Issuer Bid
Brief: Crescita Secures Contract Manufacturing Revenue Of $10 Mln Over 4 Years
Brief: Crescita Says Leading Canadian Healthcare Services Provider Selects Co As Exclusive Manufacturing Partner
Brief: Crescita Completes Acquisition Of Strategic Assets Of Occy Laboratory
Brief: Crescita To Acquire Strategic Assets Of Occy Laboratory
Brief: Crescita Therapeutics Q4 revenue CAD 4.725 million
Brief: Crescita Therapeutics Announces Approval Of Normal Course Issuer Bid
Brief: Crescita Therapeutics Inc Reports Quarterly EPS Of $0.06
Brief: Crescita Reports Third Quarter 2022 Results
Brief: Crescita Reports Q2 Revenue Of $6.5 Mln, Up From $3 Mln
Brief: Crescita Reports First Quarter 2022 Results
Brief: Crescita Reports Q4 And Fiscal 2021 Results